Quantcast

Oxurion enrolls patients to test its antibody PlGF in combinationwith Ranibizumab, to treat Diabetic Macular Edema

Belgian Oxurion has enrolled 70 patients for Phase 2 testing of its THR-317, a humanized antibody against placental growth factor (PlGF), in combination with anti-VEGF (ranibizumab), an anti-vascular endothelial growth factor (VEGF) antibody, for the treatment of Diabetic Macular Edema (DME).

Read more